Page last updated: 2024-10-28

hydroxychloroquine and Retinal Degeneration

hydroxychloroquine has been researched along with Retinal Degeneration in 7 studies

Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.

Retinal Degeneration: A retrogressive pathological change in the retina, focal or generalized, caused by genetic defects, inflammation, trauma, vascular disease, or aging. Degeneration affecting predominantly the macula lutea of the retina is MACULAR DEGENERATION. (Newell, Ophthalmology: Principles and Concepts, 7th ed, p304)

Research Excerpts

ExcerptRelevanceReference
"Cohort of 301 patients receiving long-term hydroxychloroquine therapy at Kaiser Permanente Northern California who underwent a minimum of 4 OCT studies that included Early Treatment Diabetic Retinopathy Study (ETDRS) retinal thickness values over a minimum of 4 years."4.12Rapid Macular Thinning Is an Early Indicator of Hydroxychloroquine Retinal Toxicity. ( Marmor, MF; Melles, RB, 2022)
"A patient in her late 50s with antiphospholipid syndrome presented to general ophthalmology clinic for annual hydroxychloroquine retinopathy screening."4.12Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate. ( Baxter, SL; Delavar, A, 2022)
"In untreated rheumatoid arthritis 20% of the patients has a EOG Lp/Dt ratio lower than the lower 5% limit calculated for normal patients."1.27The EOG in rheumatoid arthritis. ( Broekhuyse, RM; Pinckers, A, 1983)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19902 (28.57)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (28.57)24.3611
2020's3 (42.86)2.80

Authors

AuthorsStudies
Melles, RB1
Marmor, MF1
Joharjy, H1
Pisella, PJ1
Audo, I1
Le-Lez, ML1
Delavar, A3
Baxter, SL3
Yusuf, IH1
Lotery, AJ1
Ardern-Jones, MR1
Yao, J1
Qiu, Y1
Frontera, E1
Jia, L1
Khan, NW1
Klionsky, DJ1
Ferguson, TA1
Thompson, DA1
Zacks, DN1
Pinckers, A1
Broekhuyse, RM1
Reich, H1

Reviews

1 review available for hydroxychloroquine and Retinal Degeneration

ArticleYear
[Acrodermatitis enteropathica. Clinical picture, life-saving treatment, therapy-induced blindness].
    Deutsche medizinische Wochenschrift (1946), 1973, Sep-07, Volume: 98, Issue:36

    Topics: Acrodermatitis; Blindness; Gastrointestinal Diseases; Humans; Hydroxychloroquine; Infant; Iodoquinol

1973

Other Studies

6 other studies available for hydroxychloroquine and Retinal Degeneration

ArticleYear
Rapid Macular Thinning Is an Early Indicator of Hydroxychloroquine Retinal Toxicity.
    Ophthalmology, 2022, Volume: 129, Issue:9

    Topics: Antirheumatic Agents; Diabetic Retinopathy; Humans; Hydroxychloroquine; Retina; Retinal Degeneration

2022
A Rare Case of Didanosine-Induced Mid-Peripheral Chorioretinal Atrophy Identified Incidentally 11 Years after the Drug Cessation.
    Medicina (Kaunas, Lithuania), 2022, May-30, Volume: 58, Issue:6

    Topics: Adult; Atrophy; Choroid Diseases; Didanosine; Emtricitabine; Female; HIV Infections; Humans; Hydroxy

2022
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
    BMJ case reports, 2022, Nov-16, Volume: 15, Issue:11

    Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H

2022
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
    BMJ case reports, 2022, Nov-16, Volume: 15, Issue:11

    Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H

2022
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
    BMJ case reports, 2022, Nov-16, Volume: 15, Issue:11

    Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H

2022
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
    BMJ case reports, 2022, Nov-16, Volume: 15, Issue:11

    Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H

2022
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
    BMJ case reports, 2022, Nov-16, Volume: 15, Issue:11

    Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H

2022
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
    BMJ case reports, 2022, Nov-16, Volume: 15, Issue:11

    Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H

2022
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
    BMJ case reports, 2022, Nov-16, Volume: 15, Issue:11

    Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H

2022
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
    BMJ case reports, 2022, Nov-16, Volume: 15, Issue:11

    Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H

2022
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
    BMJ case reports, 2022, Nov-16, Volume: 15, Issue:11

    Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H

2022
Joint recommendations for retinal screening in long-term users of hydroxychloroquine and chloroquine in the United Kingdom, 2018.
    The British journal of dermatology, 2018, Volume: 179, Issue:4

    Topics: Humans; Hydroxychloroquine; Mass Screening; Patient Education as Topic; Practice Guidelines as Topic

2018
Inhibiting autophagy reduces retinal degeneration caused by protein misfolding.
    Autophagy, 2018, Volume: 14, Issue:7

    Topics: Animals; Autophagy; Autophagy-Related Protein 5; Beclin-1; Hydroxychloroquine; Mice, Inbred C57BL; M

2018
The EOG in rheumatoid arthritis.
    Acta ophthalmologica, 1983, Volume: 61, Issue:5

    Topics: Aged; Arthritis, Rheumatoid; Autoimmune Diseases; Chloroquine; Electrooculography; Female; Humans; H

1983